title: Short Communication: (18)F-immuno-PET: Determination of anti-CD66 biodistribution in a patient with high-risk leukemia.
abstract: The monoclonal antibody anti-CD66 labeled with (99m)Tc is widely used as Scintimun granulocyte for bone marrow immunoscintigraphy. Further, recently performed clinical radioimmunotherapy studies with [(90)Y]Y-anti-CD66 proved to be suitable for the treatment of hematologic malignancies. Before radioimmunotherapy with [(90)Y]Y-anti-CD66, dosimetric estimations are required to minimize radiotoxicity and determine individual applicable activities. Planar imaging, using gamma-emitting radionuclides, is conventionally carried out to estimate the absorbed organ doses. In contrast, immuno-PET (positron emission tomography) enables the quantification of anti-CD66 accumulation and provides better spatial and temporal resolution. Therefore, in this study, a semiautomated radiosynthesis of [(18)F]F-anti-CD66 was developed, using the (18)F-acylation agent, N-succinimidyl-4-[(18)F]fluorobenzoate ([(18)F]SFB). As a proof of concept, an intraindividual comparison between PET and conventional scintigraphy, using (18)F- and (99m)Tc-labeled anti-CD66 in 1 patient with high-risk leukemia, is presented. Both labeled antibodies displayed a similar distribution pattern with high preferential uptake in bone marrow. Urinary excretion of [(18)F]F-anti-CD66 was increased and bone marrow uptake reduced, in comparison to [(99m)Tc]Tc-anti-CD66. Nevertheless, PET-based dosimetry with [(18)F]F-anti-CD66 could provide additional information to support conventional scintigraphy. Moreover, [(18)F]F-anti-CD66 is ideally suited for bone marrow imaging using PET.
authors.affiliation: Department of Nuclear Medicine, University of Ulm, Germany. bernd.neumaier@nf.mpg.de <bernd.neumaier@nf.mpg.de>
authors.forename: Bernd
authors.initials: B
authors.lastname: Neumaier
authors.forename: Felix M
authors.initials: FM
authors.lastname: Mottaghy
authors.forename: Andreas K
authors.initials: AK
authors.lastname: Buck
authors.forename: Gerhard
authors.initials: G
authors.lastname: Glatting
authors.forename: Norbert M
authors.initials: NM
authors.lastname: Blumstein
authors.forename: Bettina
authors.initials: B
authors.lastname: Mahren
authors.forename: Andreas T J
authors.initials: AT
authors.lastname: Vogg
authors.forename: Sven N
authors.initials: SN
authors.lastname: Reske
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics*; D015703:Antigens, CD / Q000276:immunology*; D001853:Bone Marrow / Q000000981:diagnostic imaging; D015815:Cell Adhesion Molecules / Q000276:immunology*; D005462:Fluorine Radioisotopes / Q000493:pharmacokinetics*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000378:metabolism* / Q000628:therapy; D008297:Male; D049268:Positron-Emission Tomography; D016499:Radioimmunotherapy; D012307:Risk Factors; D014018:Tissue Distribution
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; C069847:CD66 antigens; D015815:Cell Adhesion Molecules; D005462:Fluorine Radioisotopes